ONXEO (EPA:ALONX) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
ONXEO

PRESS RELEASE

published on 08/05/2024 at 19:18, 3 months 15 days ago

Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Bilan semestriel du contrat de liquidité entre Valerio Therapeutics et Kepler Cheuvreux. Détails des moyens et transactions au 30 juin 2024

Contrat De Liquidité Bilan Semestriel Transactions Kepler Cheuvreux Valerio Therapeutics
PRESS RELEASE

published on 08/05/2024 at 19:18, 3 months 15 days ago

Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Valerio Therapeutics releases half-year liquidity contract statement revealing shares and trading volumes

Liquidity Contract Shares AMF Decision Valerio Therapeutics Trading Volumes
BRIEF

published on 06/05/2024 at 07:05, 5 months 16 days ago

Minutes of the general meeting of Valerio Therapeutics

Biotechnology Voting Results General Meeting Resolutions Valerio Therapeutics
BRIEF

published on 06/05/2024 at 07:05, 5 months 16 days ago

Compte rendu de l'assemblée générale de Valerio Therapeutics

Biotechnologie Assemblée Générale Resolutions Valerio Therapeutics Résultats De Votes
PRESS RELEASE

published on 06/05/2024 at 07:00, 5 months 16 days ago

Informations privilégiées / Autres communiqués
Valerio Therapeutics a tenu son assemblée générale mixte avec succès, adoptant toutes les résolutions du Conseil d'Administration. La Société se spécialise dans le développement de médicaments innovants ciblant les mécanismes de réponse aux dommages de l’ADN tumoral et les oncogènes pilotes

Biotechnologie Assemblée Générale Cancer Valerio Therapeutics ADN Tumoral
PRESS RELEASE

published on 06/05/2024 at 07:00, 5 months 16 days ago

Inside Information / Other news releases
Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website

Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
BRIEF

published on 05/22/2024 at 20:51, 5 months 29 days ago

Valerio Therapeutics fait progresser l'essai clinique VIO-01 avec des résultats positifs

Essai Clinique Développement De Médicaments VIO-01 Valerio Thérapeutique Tumeurs Solides
BRIEF

published on 05/22/2024 at 20:51, 5 months 29 days ago

Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results

Drug Development Solid Tumors Clinical Trial Valerio Therapeutics VIO-01
PRESS RELEASE

published on 05/22/2024 at 20:46, 5 months 29 days ago

Informations privilégiées / Autres communiqués
Valerio Therapeutics annonce l'achèvement du dosage de la première cohorte de sujets dans son essai clinique de phase 1/2 VIO-01 pour traiter les tumeurs solides sans événements indésirables graves rapportés

Biotechnologie Essai Clinique Valerio Therapeutics VIO-01 Tumeurs Solides
PRESS RELEASE

published on 05/22/2024 at 20:46, 5 months 29 days ago

Inside Information / Other news releases
Valerio Therapeutics completes dosing for first cohort of subjects in Phase 1/2 VIO-01 trial for solid tumors, showing encouraging tolerability. Phase 1b aims to determine recommended dose in selected solid tumors

Solid Tumors Valerio Therapeutics VIO-01 Trial Phase 1/2 DNA Damage Response

Accesswire

Published on 11/21/2024 at 12:00, 41 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 41 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 11 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 38 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 41 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 5 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 25 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 34 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 40 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 10 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 43 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 43 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 43 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 33 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 20 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE